Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
SYHX-1901 in Plaque psoriasis: NCT06943950 Clinical Landscape Report 2026
16 October 2026
NCT06943950 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KT-621 in Dermatitis, Atopic: NCT06945458 Clinical Landscape Report 2026
16 October 2026
NCT06945458 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Picankibart in Plaque psoriasis: NCT06945107 Clinical Landscape Report 2026
16 October 2026
NCT06945107 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GHZ339 in Dermatitis, Atopic: NCT06947993 Clinical Landscape Report 2026
16 October 2026
NCT06947993 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CM512 in Dermatitis, Atopic: NCT06947980 Clinical Landscape Report 2026
16 October 2026
NCT06947980 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
STX-0712 in Acute Monocytic Leukemia: NCT06950034 Clinical Landscape Report 2026
16 October 2026
NCT06950034 clinical landscape for Acute Monocytic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
QLS12010 in Rheumatoid Arthritis: NCT06946641 Clinical Landscape Report 2026
16 October 2026
NCT06946641 clinical landscape for Rheumatoid Arthritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Elranatamab in Recurrent Multiple Myeloma: NCT06947083 Clinical Landscape Report 2026
16 October 2026
NCT06947083 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Daratumumab in Recurrent Multiple Myeloma: NCT06948084 Clinical Landscape Report 2026
16 October 2026
NCT06948084 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fluzoparib in HRD-positive Ovarian Cancer: NCT06954584 Clinical Landscape Report 2026
16 October 2026
NCT06954584 clinical landscape for HRD-positive Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Velinotamig in Extramedullary Plasmacytoma: NCT06952075 Clinical Landscape Report 2026
16 October 2026
NCT06952075 clinical landscape for Extramedullary Plasmacytoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Surzetoclax in Relapse multiple myeloma: NCT06953960 Clinical Landscape Report 2026
16 October 2026
NCT06953960 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.